Prognostic Impact of Sarcopenia Following Myocardial Infarction: A Systematic Review and Meta-analysis of Mortality and Recurrent MI
Clicks: 1
ID: 317841
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #182 of 194 articles by views in european journal of preventive cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AIM: Sarcopenia, defined as progressive loss of skeletal muscle mass and function, may influence cardiovascular outcomes, yet its prognostic role after myocardial infarction (MI) remains uncertain. This study aimed to assess the association between sarcopenia and outcomes following MI, focusing on all-cause mortality and recurrent MI. METHODS AND RESULTS: We registered a protocol (PROSPERO CRD420251048284) and searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library to January 2025. Eligible observational cohorts assessed sarcopenia at or shortly after an index MI using validated definitions (CT, DXA, or laboratory proxies). The primary outcome was all-cause mortality; recurrent MI was secondary. Four post-MI cohorts (n = 939) showed higher mortality in patients with sarcopenia (pooled OR, 2.84; 95% CI, 1.85-4.36; I2 = 0%). Effects were consistent at ≤12 months (OR, 2.55; 95% CI, 1.42-4.58) and >12 months (OR, 3.21; 95% CI, 1.72-6.02). Only two cohorts reported recurrent MI: the pooled estimate suggested a possible increased risk but was highly imprecise and heterogeneous (OR, 2.21; 95% CI, 0.22-22.06; I2 = 81%), precluding definitive conclusions. Three PCI all-comer cohorts, analyzed as sensitivity only, also indicated higher mortality. Certainty of evidence was moderate for mortality and very low for recurrent MI. CONCLUSIONS: Sarcopenia assessed around the time of MI is consistently associated with a threefold increase in all-cause mortality, with robust effects across short- and long-term follow-up. Evidence for recurrent MI remains exploratory. Routine muscle assessment may enhance post-MI risk stratification, and multicentre cohorts with standardized definitions are needed to determine whether targeting sarcopenia can improve outcomes.
| Reference Key |
openalex_W7165189429
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xiaoyong Hu, Djandan Tadum Arthur Vithran, Mane Ngom Ulrich Parfait, Yuanyuan Dou, Hongjian Li |
| Journal | european journal of preventive cardiology |
| Year | 2026 |
| DOI |
10.1093/eurjpc/zwag329
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.